Rockwell Medical (RMTI) Cash & Equivalents (2010 - 2026)

Rockwell Medical (RMTI) has reported Cash & Equivalents for 17 consecutive years, with $10.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 15.73% year-over-year to $10.5 million; the trailing twelve-month figure through Jun 2026 stood at $10.5 million (down 15.73% YoY), and the FY2025 full-year result was $10.7 million, down 31.61% from the prior year.
• Cash & Equivalents rose to $10.5 million in Q2 2026 per RMTI's latest filing, from $9.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $30.8 million in Q2 2022 and bottomed at $6.6 million in Q1 2024.
• Historically, Cash & Equivalents has averaged $12.0 million across 5 years, with a median of $10.8 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents plunged 72.21% in 2022, then surged 74.35% in 2024.
• Over 5 years, Cash & Equivalents stood at $10.1 million in 2022, then dropped by 11.08% to $9.0 million in 2023, then surged by 74.35% to $15.7 million in 2024, then plunged by 31.61% to $10.7 million in 2025, then retreated by 1.79% to $10.5 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $10.5 million, $9.6 million, and $10.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.